Citadel Advisors’s ENDRA Life Sciences NDRA Stock Holding History

Citadel Advisors’s Portfolio NDRA Stock Details NDRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$159K	Buy	+29,924	New	+$152K	﹤0.01%	12295
2023 Q3	–	Sell	-21	Closed	-$52.1K	–	14811
2023 Q2	$52.1K	Buy	+21	New	+$59.1K	﹤0.01%	11750
2022 Q4	–	Sell	-2	Closed	-$23K	–	15252
2022 Q3	$23K	Buy	+2	New	+$20.7K	﹤0.01%	12022
2022 Q1	–	Sell	-1	Closed	-$34K	–	14241
2021 Q4	$34K	Buy	+1	New	+$42.5K	﹤0.01%	13425
2021 Q3	–	Hold	0	–	–	–	13603
2021 Q2	–	Sell	-1	Closed	-$130K	–	14140
2021 Q1	$130K	Buy	+1	New	+$74.9K	﹤0.01%	12201
2020 Q4	–	Sell	-1	Closed	-$33K	–	11302
2020 Q3	$33K	Hold	1	–	–	﹤0.01%	9738
2020 Q2	$36K	Buy	+1	New	+$29K	﹤0.01%	9416
2019 Q2	–	Sell	-1	Closed	-$29K	–	9623
2019 Q1	$29K	Buy	+1	New	+$73K	﹤0.01%	9003
2018 Q4	–	Hold	0	–	–	–	8733

Other funds holding NDRA

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

CFG

Citizens Financial Group Providence, Rhode Island $8.3B AUM 27.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $187B AUM 21.7% 1-Year Est. Return

Citadel Advisors's NDRA Position: Q2 2026 in Review

Citadel Advisors opened a new position in ENDRA Life Sciences (NDRA) in Q2 2026: 29,924 shares worth $159K. The stake represents ﹤0.01% of the portfolio and ranks #12295 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in NDRA as recently as Q2 2023.

Citadel Advisors first reported a position in NDRA in Q1 2019 and has held it in 8 quarters since. 10 funds tracked by Wall St. Rank hold NDRA as of Q2 2026.

Citadel Advisors held 29,924 shares of ENDRA Life Sciences worth $159K as of Q2 2026.
ENDRA Life Sciences was a new Citadel Advisors position in Q2 2026.
ENDRA Life Sciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12295 holding.
Citadel Advisors first reported a position in ENDRA Life Sciences in Q1 2019 and has held it in 8 quarters since.
10 funds tracked by Wall St. Rank held ENDRA Life Sciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.